DGIdb - UGT1A1 Gene Record

UGT1A1 54658 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

54658
UDP GLUCURONOSYLTRANSFERASE FAMILY 1 MEMBER A1
UGT1A1
BILIQTL1
GNT1
HUG-BR1
UDPGT
UDPGT 1-1
UGT1
UGT1A
191740
12530
ENSG00000241635
OTTHUMG00000059117
PA420
P22309
12422
UDP-glucuronosyltransferase 1-1
2990
NP_000454
BE0003541

Gene Info:

Gene Biotype	PROTEIN_CODING
GuideToPharmacology Gene Category Name	UDP glucuronosyltransferases (UGT)
GuideToPharmacology Gene Category ID	988

(9 More Sources)

Gene Categories: Category Details

DRUG RESISTANCE
DRUGGABLE GENOME
DRUG METABOLISM
CLINICALLY ACTIONABLE
ENZYME

Publications:

Bhatt DK et al., 2019, Age- and Genotype-Dependent Variability in the Protein Abundance and Activity of Six Major Uridine Diphosphate-Glucuronosyltransferases in Human Liver., Clin Pharmacol Ther
An SH et al., 2015, Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves., Cardiovasc Ther
Kobie J et al., 2019, Pharmacogenetic Analysis of OATP1B1, UGT1A1, and BCRP Variants in Relation to the Pharmacokinetics of Letermovir in Previously Conducted Clinical Studies., J Clin Pharmacol
Carroll MB et al., 2017, Genomic sequencing of uric acid metabolizing and clearing genes in relationship to xanthine oxidase inhibitor dose., Rheumatol Int
Haas DW et al., 2014, Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes., J Antimicrob Chemother
Goey et al., 2016, Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer., J Clin Pharmacol
Motzer RJ et al., 2013, Hyperbilirubinemia in pazopanib- or sunitinib-treated patients in COMPARZ is associated with UGT1A1 polymorphisms., Ann Oncol
Yamasaki S et al., 2015, UGT1A1 *6 polymorphism predicts outcome in elderly patients with relapsed or refractory diffuse large B-cell lymphoma treated with carboplatin, dexamethasone, etoposide and irinotecan., Ann Hematol
Abumiya M et al., 2014, Influence of UGT1A1 6, 27, and 28 polymorphisms on nilotinib-induced hyperbilirubinemia in Japanese patients with chronic myeloid leukemia., Drug Metab Pharmacokinet
Singer JB et al., 2007, UGT1A1 promoter polymorphism increases risk of nilotinib-induced hyperbilirubinemia., Leukemia
Chen S et al., 2014, Evaluation of the effect of UGT1A1 polymorphisms on dolutegravir pharmacokinetics., Pharmacogenomics
Ciotti M et al., 1999, Glucuronidation of 7-ethyl-10-hydroxycamptothecin (SN-38) by the human UDP-glucuronosyltransferases encoded at the UGT1 locus., Biochem Biophys Res Commun
Hu ZY et al., 2010, Dose-dependent association between UGT1A1*28 genotype and irinotecan-induced neutropenia: low doses also increase risk., Clin Cancer Res
Ramesh et al., 2010, Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives., Biomed. Chromatogr.
Onoue M et al., 2009, UGT1A1*6 polymorphism is most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients., Int J Clin Oncol
Cecchin E et al., 2009, Predictive role of the UGT1A1, UGT1A7, and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil, leucovorin, and irinotecan., J Clin Oncol
Obradovic M et al., 2008, Cost-effectiveness of UGT1A1 genotyping in second-line, high-dose, once every 3 weeks irinotecan monotherapy treatment of colorectal cancer., Pharmacogenomics
Lankisch TO et al., 2008, Gilbert's Syndrome and irinotecan toxicity: combination with UDP-glucuronosyltransferase 1A7 variants increases risk., Cancer Epidemiol Biomarkers Prev
Hoskins JM et al., 2007, UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters., J Natl Cancer Inst
Lankisch TO et al., 2006, Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype., Hepatology
Kawato Y et al., 1991, Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11., Cancer Res
Danoff TM et al., 2004, A Gilbert's syndrome UGT1A1 variant confers susceptibility to tranilast-induced hyperbilirubinemia., Pharmacogenomics J
Kishi S et al., 2004, Effects of prednisone and genetic polymorphisms on etoposide disposition in children with acute lymphoblastic leukemia., Blood
Gagné JF et al., 2002, Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38)., Mol Pharmacol
Kemp DC et al., 2002, Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance., Drug Metab Dispos
Guillemette C et al., 2000, Structural heterogeneity at the UDP-glucuronosyltransferase 1 locus: functional consequences of three novel missense mutations in the human UGT1A7 gene., Pharmacogenetics
Sai K et al., 2004, UGT1A1 haplotypes associated with reduced glucuronidation and increased serum bilirubin in irinotecan-administered Japanese patients with cancer., Clin Pharmacol Ther
Iolascon A et al., 1999, (TA)8 allele in the UGT1A1 gene promoter of a Caucasian with Gilbert's syndrome., Haematologica
Akaba K et al., 1998, Neonatal hyperbilirubinemia and mutation of the bilirubin uridine diphosphate-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese., Biochem Mol Biol Int
Strassburg CP et al., 1998, Polymorphic expression of the UDP-glucuronosyltransferase UGT1A gene locus in human gastric epithelium., Mol Pharmacol
Yamamoto K et al., 1998, Contribution of two missense mutations (G71R and Y486D) of the bilirubin UDP glycosyltransferase (UGT1A1) gene to phenotypes of Gilbert's syndrome and Crigler-Najjar syndrome type II., Biochim Biophys Acta
Bosma PJ et al., 1994, Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man., J Biol Chem
Bosma PJ et al., 1995, The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome., N Engl J Med
Arias IM et al., 1969, Chronic nonhemolytic unconjugated hyperbilirubinemia with glucuronyl transferase deficiency. Clinical, biochemical, pharmacologic and genetic evidence for heterogeneity., Am J Med
Pett S et al., 1987, Crigler-Najjar syndrome types I and II. Clinical experience--King's College Hospital 1972-1978. Phenobarbitone, phototherapy and liver transplantation., Mol Aspects Med
Stender S et al., 2013, Genetically elevated bilirubin and risk of ischaemic heart disease: three Mendelian randomization studies and a meta-analysis., J Intern Med
Bajro MH et al., 2012, Promoter length polymorphism in UGT1A1 and the risk of sporadic colorectal cancer., Cancer Genet
James RE et al., 2011, Postmenopausal serum sex steroids and risk of hormone receptor-positive and -negative breast cancer: a nested case-control study., Cancer Prev Res (Phila)
Lin JP et al., 2010, Serum bilirubin and genes controlling bilirubin concentrations as biomarkers for cardiovascular disease., Clin Chem
Ekblom K et al., 2010, Plasma bilirubin and UGT1A1*28 are not protective factors against first-time myocardial infarction in a prospective, nested case-referent setting., Circ Cardiovasc Genet
Sneitz N et al., 2010, Crigler-Najjar syndrome in The Netherlands: identification of four novel UGT1A1 alleles, genotype-phenotype correlation, and functional analysis of 10 missense mutants., Hum Mutat
Ritter JK et al., 1991, Cloning of two human liver bilirubin UDP-glucuronosyltransferase cDNAs with expression in COS-1 cells., J Biol Chem
Strassburg CP, 2008, Pharmacogenetics of Gilbert's syndrome., Pharmacogenomics
Tsezou A et al., 2007, Genetic polymorphisms in the UGT1A1 gene and breast cancer risk in Greek women., Genet Test
Zhang D et al., 2007, Characterization of the UDP glucuronosyltransferase activity of human liver microsomes genotyped for the UGT1A1*28 polymorphism., Drug Metab Dispos
Lin JP et al., 2006, Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study., Circulation
Boyd MA et al., 2006, Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir., Pharmacogenet Genomics
Girard H et al., 2005, UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver., Hepatology
Servedio V et al., 2005, Spectrum of UGT1A1 mutations in Crigler-Najjar (CN) syndrome patients: identification of twelve novel alleles and genotype-phenotype correlation., Hum Mutat
Adegoke OJ et al., 2004, Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 (UGT1A1) and risk of breast cancer., Breast Cancer Res Treat
Schauer R et al., 2003, Treatment of Crigler-Najjar type 1 disease: relevance of early liver transplantation., J Pediatr Surg
Bosma PJ et al., 2003, UGT1A1*28 allele and coronary heart disease: the Rotterdam Study., Clin Chem
Williams JA et al., 2002, Differential modulation of UDP-glucuronosyltransferase 1A1 (UGT1A1)-catalyzed estradiol-3-glucuronidation by the addition of UGT1A1 substrates and other compounds to human liver microsomes., Drug Metab Dispos
Tukey RH et al., 2002, Pharmacogenomics of human UDP-glucuronosyltransferases and irinotecan toxicity., Mol Pharmacol
Fang JL et al., 2002, Characterization of benzo(a)pyrene-trans-7,8-dihydrodiol glucuronidation by human tissue microsomes and overexpressed UDP-glucuronosyltransferase enzymes., Cancer Res
Guillemette C et al., 2001, Association of genetic polymorphisms in UGT1A1 with breast cancer and plasma hormone levels., Cancer Epidemiol Biomarkers Prev
Kadakol A et al., 2000, Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype., Hum Mutat
Tukey RH et al., 2000, Human UDP-glucuronosyltransferases: metabolism, expression, and disease., Annu Rev Pharmacol Toxicol
Strassburg CP et al., 2000, Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine., J Biol Chem
Guillemette C et al., 2000, Genetic polymorphisms in uridine diphospho-glucuronosyltransferase 1A1 and association with breast cancer among African Americans., Cancer Res
Maruo Y et al., 1999, Association of neonatal hyperbilirubinemia with bilirubin UDP-glucuronosyltransferase polymorphism., Pediatrics
Monaghan G et al., 1999, Gilbert's syndrome is a contributory factor in prolonged unconjugated hyperbilirubinemia of the newborn., J Pediatr
Hongkaew Y et al., 2018, UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder., Pharmacogenomics J
Turatti L et al., 2012, Short communication: UGT1A1*28 variant allele is a predictor of severe hyperbilirubinemia in HIV-infected patients on HAART in southern Brazil., AIDS Res Hum Retroviruses
Park WB et al., 2010, Genetic factors influencing severe atazanavir-associated hyperbilirubinemia in a population with low UDP-glucuronosyltransferase 1A1*28 allele frequency., Clin Infect Dis
Hu ZY et al., 2010, Dose-dependent association between UGT1A1*28 polymorphism and irinotecan-induced diarrhoea: a meta-analysis., Eur J Cancer
Takano M et al., 2009, Clinical significance of UDP-glucuronosyltransferase 1A1*6 for toxicities of combination chemotherapy with irinotecan and cisplatin in gynecologic cancers: a prospective multi-institutional study., Oncology
Jada SR et al., 2007, Role of UGT1A16, UGT1A128 and ABCG2 c.421C>A polymorphisms in irinotecan-induced neutropenia in Asian cancer patients., Cancer Sci
Urawa N et al., 2006, Linkage disequilibrium of UGT1A1 6 and UGT1A1 28 in relation to UGT1A6 and UGT1A7 polymorphisms., Oncol Rep
Toffoli G et al., 2006, The role of UGT1A1*28 polymorphism in the pharmacodynamics and pharmacokinetics of irinotecan in patients with metastatic colorectal cancer., J Clin Oncol
Massacesi et al., 2006, Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy., Cancer
Rotger M et al., 2005, Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia., J Infect Dis
Zhang D et al., 2005, In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation., Drug Metab Dispos
Carlini et al., 2005, UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan., Clin. Cancer Res.
Rouits E et al., 2004, Relevance of different UGT1A1 polymorphisms in irinotecan-induced toxicity: a molecular and clinical study of 75 patients., Clin Cancer Res
Innocenti F et al., 2004, Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan., J Clin Oncol
Ando Y et al., 2000, Polymorphisms of UDP-glucuronosyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis., Cancer Res
Hall D et al., 1999, Variability at the uridine diphosphate glucuronosyltransferase 1A1 promoter in human populations and primates., Pharmacogenetics
Zientek MA et al., 2016, In Vitro Kinetic Characterization of Axitinib Metabolism., Drug Metab Dispos
Cabaleiro T et al., 2013, Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects., Hum Psychopharmacol
Lui G et al., 2018, A Pharmacokinetic and Pharmacogenetic Analysis of Osteosarcoma Patients Treated With High-Dose Methotrexate: Data From the OS2006/Sarcoma-09 Trial., J Clin Pharmacol
Baudhuin LM et al., 2010, Relation of ADRB1, CYP2D6, and UGT1A1 polymorphisms with dose of, and response to, carvedilol or metoprolol therapy in patients with chronic heart failure., Am J Cardiol
Takekuma Y et al., 2006, Contribution of polymorphisms in UDP-glucuronosyltransferase and CYP2D6 to the individual variation in disposition of carvedilol., J Pharm Pharm Sci
Zhou J et al., 2011, Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors., Drug Metab Dispos
Mbatchi LC et al., 2016, Effect of Single Nucleotide Polymorphisms in the Xenobiotic-sensing Receptors NR1I2 and NR1I3 on the Pharmacokinetics and Toxicity of Irinotecan in Colorectal Cancer Patients., Clin Pharmacokinet
Kim KP et al., 2015, A phase I study of UGT1A1 28/6 genotype-directed dosing of irinotecan (CPT-11) in Korean patients with metastatic colorectal cancer receiving FOLFIRI., Oncology
Han JY et al., 2009, Integrated pharmacogenetic prediction of irinotecan pharmacokinetics and toxicity in patients with advanced non-small cell lung cancer., Lung Cancer
Stewart CF et al., 2007, UGT1A1 promoter genotype correlates with SN-38 pharmacokinetics, but not severe toxicity in patients receiving low-dose irinotecan., J Clin Oncol
de Jong FA et al., 2007, Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein., Clin Pharmacol Ther
de Jong FA et al., 2006, Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study., Oncologist
Han JY et al., 2006, Comprehensive analysis of UGT1A polymorphisms predictive for pharmacokinetics and treatment outcome in patients with non-small-cell lung cancer treated with irinotecan and cisplatin., J Clin Oncol
Iyer L et al., 2002, UGT1A1*28 polymorphism as a determinant of irinotecan disposition and toxicity., Pharmacogenomics J
Erickson-Ridout KK et al., 2012, Glucuronidation of the second-generation antipsychotic clozapine and its active metabolite N-desmethylclozapine. Potential importance of the UGT1A1 A(TA)₇TAA and UGT1A4 L48V polymorphisms., Pharmacogenet Genomics
Rolf MG et al., 2015, In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib., Pharmacol Res Perspect

BILIRUBIN UGT1A1

Interaction Score: 13.47

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15179405 10091406 9784835 9765507 9630669 8027054 7565971 4897277 3306242 22805420 22559977 21813404 20693308 20562445 19830808 1898728 18518849 17949292 17898154 17000907 16609363 15986396 15712364 15111762 12891498 12816916 12386134 12181419 11929814 11401924 11013440 10836148 10748067 10706110 10353933 10190918

Sources:
PharmGKB
INDINAVIR UGT1A1

Interaction Score: 3.79

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10353933 9784835 9630669 7565971 22050734 20562211 20504240 20335017 19390945 19299905 17728214 17627617 17058217 16969497 16809730 16609363 16456808 16170755 16118329 15709193 15297419 15007088 12181419 11156391 10591539

Sources:
PharmGKB
TRANILAST UGT1A1

Interaction Score: 2.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10381366 20562211 19852077 19390945 19364970 18466101 18349289 17728214 17058217 1651156 14647407 12969965 12181437 12019197 11037804

Sources:
PharmGKB
7-ETHYL-10-HYDROXYCAMPTOTHECIN UGT1A1

Interaction Score: 1.46

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27116457 25427841 18221820 17627617 17577039 17185998 16951398 16636344 15179405 15007088 11990381 10381366 20562211 19852077 19390945 19364970 18466101 18349289 17728214 17058217 1651156 14647407 12969965 12181437 12019197 11037804

Sources:
PharmGKB
LETERMOVIR UGT1A1

Interaction Score: 1.46

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
31022310

Sources:
PharmGKB
DOLUTEGRAVIR UGT1A1

Interaction Score: 0.87

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24329186

Sources:
PharmGKB FDA
RALOXIFENE UGT1A1

Interaction Score: 0.73

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
10381366 20562211 19852077 19390945 19364970 18466101 18349289 17728214 17058217 1651156 14647407 12969965 12181437 12019197 11037804

Sources:
PharmGKB
RALTEGRAVIR UGT1A1

Interaction Score: 0.73

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
FDA
ARFORMOTEROL UGT1A1

Interaction Score: 0.73

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
INDACATEROL UGT1A1

Interaction Score: 0.73

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
NILOTINIB UGT1A1

Interaction Score: 0.56

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family BCR-ABL inhibitor 2nd gen

Alteration UGT1A1:.

Alteration UGT1A1:G71R,P229Q

PMIDs:
24898899 17611564

Sources:
CGI PharmGKB FDA
ETOPOSIDE UGT1A1

Interaction Score: 0.48

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25055799 10381366 20562211 19852077 19390945 19364970 18466101 18349289 17728214 17058217 1651156 14647407 12969965 12181437 12019197 11037804

Sources:
PharmGKB
BELINOSTAT UGT1A1

Interaction Score: 0.31

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26313268

Sources:
CIViC FDA
FEBUXOSTAT UGT1A1

Interaction Score: 0.24

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27798726

Sources:
PharmGKB
ETHINYL ESTRADIOL UGT1A1

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21030469

Sources:
DTC
AXITINIB UGT1A1

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
26512042

Sources:
PharmGKB
LOSARTAN UGT1A1

Interaction Score: 0.16

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
EFAVIRENZ UGT1A1

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24729586

Sources:
PharmGKB
CARVEDILOL UGT1A1

Interaction Score: 0.14

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
20643254 16849011

Sources:
PharmGKB
BINIMETINIB UGT1A1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB FDA
PAZOPANIB UGT1A1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family VEGFR inhibitor

Alteration UGT1A1:.

PMIDs:
24107802

Sources:
CGI PharmGKB FDA
DAIDZEIN UGT1A1

Interaction Score: 0.13

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
21030469

Sources:
DTC
WARFARIN UGT1A1

Interaction Score: 0.12

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29737521 26223945

Sources:
PharmGKB
ALLOPURINOL UGT1A1

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27798726

Sources:
PharmGKB
RITONAVIR UGT1A1

Interaction Score: 0.07

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Details of Interaction Both inhibitor and substrate

Endogenous Drug? False

PMIDs:
None found

Sources:
GuideToPharmacology
FLUVASTATIN UGT1A1

Interaction Score: 0.07

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
IRINOTECAN UGT1A1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

Alteration UGT1A1:G71R,P229Q

Alteration UGT1A1:.

Drug family TOPO1 inhibitor

PMIDs:
None found

Sources:
CGI FDA
RUCAPARIB UGT1A1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
RISPERIDONE UGT1A1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29955115

Sources:
PharmGKB
OLANZAPINE UGT1A1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
23559402

Sources:
PharmGKB
CARBOPLATIN UGT1A1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25055799

Sources:
PharmGKB
CLOZAPINE UGT1A1

Interaction Score: 0.04

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22565219

Sources:
PharmGKB
DEXAMETHASONE UGT1A1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25055799

Sources:
PharmGKB
LOVASTATIN UGT1A1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ERLOTINIB UGT1A1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
METHOTREXATE UGT1A1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
29791011

Sources:
PharmGKB
SIMVASTATIN UGT1A1

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
ATORVASTATIN UGT1A1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
FOSTAMATINIB UGT1A1

Interaction Score: 0.01

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

PMIDs:
26516587

Sources:
DrugBank

Ensembl: ENSG00000241635
- Version: 101_38
Alternate Names:

UGT1A1 Ensembl Gene Name

Gene Info:

Gene Biotype PROTEIN_CODING

Publications:
GuideToPharmacology: 54658
- Version: 29-September-2020
Alternate Names:

12530 HUGO Gene ID

12530 HUGO Gene Symbol

UDP glucuronosyltransferase family 1 member A1 HUGO Gene Name

Gene Info:

GuideToPharmacology Gene Category Name UDP glucuronosyltransferases (UGT)

GuideToPharmacology Gene Category ID 988

Gene Categories:

ENZYME

Publications:

PharmGKB: UGT1A1

Version: 18-August-2020

Alternate Names:

PA420 PharmGKB ID

Gene Info:

Publications:

Haas DW et al., 2014, Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes., J Antimicrob Chemother

Hongkaew Y et al., 2018, UGT1A1 polymorphisms associated with prolactin response in risperidone-treated children and adolescents with autism spectrum disorder., Pharmacogenomics J

Cabaleiro T et al., 2013, Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects., Hum Psychopharmacol

CIViC: UGT1A1

Version: 14-September-2020

Alternate Names:

54658 Entrez Gene ID

12422 CIViC Gene ID

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:

Goey et al., 2016, Effects of UGT1A1 genotype on the pharmacokinetics, pharmacodynamics, and toxicities of belinostat administered by 48-hour continuous infusion in patients with cancer., J Clin Pharmacol

DrugBank: BE0003541
- Version: 5.1.7
Alternate Names:

UGT1A1 DrugBank Gene Name

P22309 UniProt Accession

54658 Entrez Gene Id

Gene Info:

Publications:

Rolf MG et al., 2015, In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib., Pharmacol Res Perspect

DTC: UGT1A1

Version: 02-September-2020

Alternate Names:

Gene Info:

Publications:

Zhou J et al., 2011, Correlation between bilirubin glucuronidation and estradiol-3-gluronidation in the presence of model UDP-glucuronosyltransferase 1A1 substrates/inhibitors., Drug Metab Dispos

HingoraniCasas: ENSG00000241635
- Version: 31-May-2017
Alternate Names:

ENSG00000241635 Gene Symbol

UGT1A1 Ensembl Id

Gene Info:

Gene Categories:

DRUGGABLE GENOME

Publications:
HumanProteinAtlas: UGT1A1
- Version: 19.3
Alternate Names:

ENSG00000241635 Ensembl Gene ID

GNT1 Human Protein Atlas Gene Synonym

UGT1 Human Protein Atlas Gene Synonym

Gene Info:

Gene Categories:

ENZYME

Publications:
Pharos: UGT1A1
- Version: 03-September-2020
Alternate Names:

UDP-glucuronosyltransferase 1-1 Gene Name

P22309 UniProt ID

Gene Info:

Gene Categories:

ENZYME

Publications:
GO: UGT1A1
- Version: 05-September-2020
Alternate Names:

GNT1 GO Gene Synonym

UGT1 GO Gene Synonym

Gene Info:

Gene Categories:

DRUG METABOLISM, DRUG RESISTANCE

Publications:
Tempus: UGT1A1
- Version: 11-November-2018
Alternate Names:

UGT1A1 Gene Symbol

Gene Info:

Gene Categories:

CLINICALLY ACTIONABLE

Publications:
CGI: UGT1A1
- Version: 27-September-2017
Alternate Names:

Gene Info:

Publications:
FDA: UGT1A1
- Version: 04-September-2020
Alternate Names:

Gene Info:

Publications:

Drug family	BCR-ABL inhibitor 2nd gen
Alteration	UGT1A1:.
Alteration	UGT1A1:G71R,P229Q

Specific Action of the Ligand	Inhibition
Details of Interaction	Both inhibitor and substrate
Endogenous Drug?	False

12530	HUGO Gene ID
12530	HUGO Gene Symbol
UDP glucuronosyltransferase family 1 member A1	HUGO Gene Name

UGT1A1	DrugBank Gene Name
P22309	UniProt Accession
54658	Entrez Gene Id

ENSG00000241635	Ensembl Gene ID
GNT1	Human Protein Atlas Gene Synonym
UGT1	Human Protein Atlas Gene Synonym

UGT1A1 Gene Record

UGT1A1 54658 Druggable GenomeClinically ActionableDrug Resistance

Alternate Names:

Gene Info:

Gene Categories: Category Details

Publications:

Interaction Types & Directionality: n/a

Interaction Info:

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10353933 9784835 9630669 7565971 22050734 20562211 20504240 20335017 19390945 19299905 17728214 17627617 17058217 16969497 16809730 16609363 16456808 16170755 16118329 15709193 15297419 15007088 12181419 11156391 10591539

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10381366 20562211 19852077 19390945 19364970 18466101 18349289 17728214 17058217 1651156 14647407 12969965 12181437 12019197 11037804

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27116457 25427841 18221820 17627617 17577039 17185998 16951398 16636344 15179405 15007088 11990381 10381366 20562211 19852077 19390945 19364970 18466101 18349289 17728214 17058217 1651156 14647407 12969965 12181437 12019197 11037804

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 31022310

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24329186

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 10381366 20562211 19852077 19390945 19364970 18466101 18349289 17728214 17058217 1651156 14647407 12969965 12181437 12019197 11037804

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info: Drug family BCR-ABL inhibitor 2nd gen Alteration UGT1A1:. Alteration UGT1A1:G71R,P229Q

PMIDs: 24898899 17611564

Sources: CGI PharmGKB FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25055799 10381366 20562211 19852077 19390945 19364970 18466101 18349289 17728214 17058217 1651156 14647407 12969965 12181437 12019197 11037804

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26313268

Sources: CIViC FDA

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 27798726

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 21030469

Sources: DTC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 26512042

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24729586

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 20643254 16849011

Interaction Types & Directionality:

n/a

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
10353933 9784835 9630669 7565971 22050734 20562211 20504240 20335017 19390945 19299905 17728214 17627617 17058217 16969497 16809730 16609363 16456808 16170755 16118329 15709193 15297419 15007088 12181419 11156391 10591539

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
10381366 20562211 19852077 19390945 19364970 18466101 18349289 17728214 17058217 1651156 14647407 12969965 12181437 12019197 11037804

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27116457 25427841 18221820 17627617 17577039 17185998 16951398 16636344 15179405 15007088 11990381 10381366 20562211 19852077 19390945 19364970 18466101 18349289 17728214 17058217 1651156 14647407 12969965 12181437 12019197 11037804

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
31022310

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24329186

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
10381366 20562211 19852077 19390945 19364970 18466101 18349289 17728214 17058217 1651156 14647407 12969965 12181437 12019197 11037804

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
FDA

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family BCR-ABL inhibitor 2nd gen

Alteration UGT1A1:.

Alteration UGT1A1:G71R,P229Q

PMIDs:
24898899 17611564

Sources:
CGI PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
25055799 10381366 20562211 19852077 19390945 19364970 18466101 18349289 17728214 17058217 1651156 14647407 12969965 12181437 12019197 11037804

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
26313268

Sources:
CIViC FDA

Interaction Types & Directionality:

n/a

PMIDs:
27798726

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
21030469

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
26512042

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24729586

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
20643254 16849011

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB FDA

Interaction Types & Directionality:

n/a

Interaction Info:

Drug family VEGFR inhibitor

Alteration UGT1A1:.

PMIDs:
24107802

Sources:
CGI PharmGKB FDA

Interaction Types & Directionality:

n/a

PMIDs:
21030469

Sources:
DTC

Interaction Types & Directionality:

n/a

PMIDs:
29737521 26223945

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
27798726

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Specific Action of the Ligand Inhibition

Details of Interaction Both inhibitor and substrate

Endogenous Drug? False

PMIDs:
None found

Sources:
GuideToPharmacology

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB